Optical frequency domain imaging-guided versus intravascular ultrasound-guided percutaneous coronary intervention for acute coronary syndromes: the OPINION ACS randomised trial.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
02 Sep 2024
Historique:
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 2 9 2024
Statut: epublish

Résumé

The clinical benefits of optical frequency domain imaging (OFDI)-guided percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) remain unclear. We sought to compare intravascular ultrasound (IVUS)- and OFDI-guided PCI in patients with ACS. OPINION ACS is a multicentre, prospective, randomised, non-inferiority trial that compared OFDI-guided PCI with IVUS-guided PCI using current-generation drug-eluting stents in ACS patients (n=158). The primary endpoint was in-stent minimum lumen area (MLA), assessed using 8-month follow-up OFDI. Patients presented with ST-segment elevation myocardial infarction (55%), non-ST-segment elevation myocardial infarction (29%), or unstable angina pectoris (16%). PCI procedural success was achieved in all patients, with comparably low periprocedural complications rates in both groups. Immediately after PCI, the minimum stent area (p=0.096) tended to be smaller for OFDI versus IVUS guidance. Proximal stent edge dissection (p=0.012) and irregular protrusion (p=0.03) were significantly less frequent in OFDI-guided procedures than in IVUS-guided procedures. Post-PCI coronary flow, assessed using corrected Thrombolysis in Myocardial Infarction frame counts, was significantly better in the OFDI-guided group than in the IVUS-guided group (p<0.001). The least squares mean (95% confidence interval [CI]) in-stent MLA at 8 months was 4.91 (95% CI: 4.53-5.30) mm Among ACS patients, OFDI-guided PCI and IVUS-guided PCI were equally safe and feasible, with comparable in-stent MLA at 8 months. OFDI guidance may be a potential option in ACS patients. This study was registered in the Japan Registry of Clinical Trials (jrct.niph.go.jp: jRCTs052190093).

Sections du résumé

BACKGROUND BACKGROUND
The clinical benefits of optical frequency domain imaging (OFDI)-guided percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) remain unclear.
AIMS OBJECTIVE
We sought to compare intravascular ultrasound (IVUS)- and OFDI-guided PCI in patients with ACS.
METHODS METHODS
OPINION ACS is a multicentre, prospective, randomised, non-inferiority trial that compared OFDI-guided PCI with IVUS-guided PCI using current-generation drug-eluting stents in ACS patients (n=158). The primary endpoint was in-stent minimum lumen area (MLA), assessed using 8-month follow-up OFDI.
RESULTS RESULTS
Patients presented with ST-segment elevation myocardial infarction (55%), non-ST-segment elevation myocardial infarction (29%), or unstable angina pectoris (16%). PCI procedural success was achieved in all patients, with comparably low periprocedural complications rates in both groups. Immediately after PCI, the minimum stent area (p=0.096) tended to be smaller for OFDI versus IVUS guidance. Proximal stent edge dissection (p=0.012) and irregular protrusion (p=0.03) were significantly less frequent in OFDI-guided procedures than in IVUS-guided procedures. Post-PCI coronary flow, assessed using corrected Thrombolysis in Myocardial Infarction frame counts, was significantly better in the OFDI-guided group than in the IVUS-guided group (p<0.001). The least squares mean (95% confidence interval [CI]) in-stent MLA at 8 months was 4.91 (95% CI: 4.53-5.30) mm
CONCLUSIONS CONCLUSIONS
Among ACS patients, OFDI-guided PCI and IVUS-guided PCI were equally safe and feasible, with comparable in-stent MLA at 8 months. OFDI guidance may be a potential option in ACS patients. This study was registered in the Japan Registry of Clinical Trials (jrct.niph.go.jp: jRCTs052190093).

Identifiants

pubmed: 39219363
pii: EIJ-D-24-00314
doi: 10.4244/EIJ-D-24-00314
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Multicenter Study Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1086-e1097

Auteurs

Hiromasa Otake (H)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Takashi Kubo (T)

Department of Cardiology, Tokyo Medical University, Hachioji Medical Center, Tokyo, Japan.

Kiyoshi Hibi (K)

Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.

Makoto Natsumeda (M)

Division of Cardiology, Tokai University School of Medicine, Isehara, Japan.

Masaru Ishida (M)

Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.

Toru Kataoka (T)

Division of Cardiology, Bell-land General Hospital, Sakai, Japan.

Tomofumi Takaya (T)

Division of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan.

Masamichi Iwasaki (M)

Department of Cardiology, Hyogo Prefectural Awaji Medical Center, Sumoto, Japan.

Shinjo Sonoda (S)

Department of Cardiovascular Medicine, Saga University, Saga, Japan.

Toshiro Shinke (T)

Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Gaku Nakazawa (G)

Department of Cardiology, Kindai University Faculty of Medicine, Osaka, Japan.

Yu Takahashi (Y)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Tetsuya Ioji (T)

Division of Medical Statistics, Translational Research Center for Medical Innovation, Kobe, Japan.

Takashi Akasaka (T)

Department of Cardiovascular Medicine, Nishinomiya Watanabe Cardiovascular Cerebral Center, Nishinomiya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH